Reinke F, Löher A, Köbe J, Eckardt L
Abteilung für Rhythmologie, Department für Kardiologie und Angiologie, Universitätsklinikum Münster, Münster, Germany.
Herzschrittmacherther Elektrophysiol. 2013 Sep;24(3):165-70. doi: 10.1007/s00399-013-0277-3.
Prevention of sudden cardiac death is one of the most important tasks of cardiology. Transvenous ICD-systems have impressively proven their effectiveness in numerous randomized trials. Transvenous systems have their limitations due to frequent long-term lead complications. Having been available for a few years, the entirely subcutaneous ICD-system (S-ICD®, Boston Scientific, USA, former Cameron Health, USA) seems to be a promising alternative despite the lack of prospective data. The implantation of the SICD® can be performed easily; lead complications are rare because of the totally subcutaneous implantation. The detection and therapy of life-threatening tachyarrhythmias seems to be safe, although inappropriate therapies are a common problem in cases of insufficient ECG screening. S-ICD® is no alternative to the transvenous system due to limited programming options and the lack of stimulation, but it is an interesting supplement of ICD therapy.
预防心源性猝死是心脏病学最重要的任务之一。经静脉植入式心脏除颤器（ICD）系统在众多随机试验中已令人印象深刻地证明了其有效性。由于频繁出现长期导线并发症，经静脉系统存在局限性。完全皮下植入式ICD系统（S-ICD®，美国波士顿科学公司，前身为美国卡梅隆健康公司）尽管缺乏前瞻性数据，但在面市几年后似乎是一种有前景的替代方案。SICD®的植入操作简便；由于完全皮下植入，导线并发症很少见。尽管在心电图筛查不足的情况下不适当治疗是一个常见问题，但危及生命的快速性心律失常的检测和治疗似乎是安全的。由于编程选项有限且缺乏起搏功能，S-ICD®不能替代经静脉系统，但它是ICD治疗的一个有趣补充。
